Elan is a bio/pharmaceutical company with roots in Ireland and the US. It has 2 primary foci: biologic treatments for neurologic indications and drug delivery.
They currently have several sources of revenue:
* Drug delivery manufacturing and R&D contract services
* Nanotechnology drug delivery licensing and manufacturing services (among major drugs approved are Tricor (5%), and Magace... major drugs in progress include Palperidone Palmitate in P3 8% royalty, and ACOR's drug 18% royalty)
* Older hospital drugs that will gradually come off patent
* Tysabri - a monoclonal antibody product approved by the FDA and EMEA for MS with Crohn's Disease decisions pending
* Prialt, an intrathecally delivered synthetic toxin for relieving pain otherwise untreatable by morphine (EU marketing/sales rights sold to Eisai 2/2006)
In R&D are:
* AAB-001 mAb for Alzheimer's Disease (P3)
* AAB-002 mAb for Alzheimer's Disease (expected IND 2007)
* AAC-001 immunoconjugate for Alzheimer's Disease (P2)
* beta secretase program for Alzheimer's Disease (pre-clinical)
* gamma secretase program for Alzheimer's Disease (pre-clinical)
* right to 50% of Eli Lilly's gamma secretase AD program (P2 completed)
* ELND-001: anti-VLA4 small molecules for RA (P1)
* ELND-002: anti-VLA4 small molecules for MS (IND in 2007?)
* AZD-103: beta amyloid oral prophylactic (P1 - in-licensed from Transition Therapeutics)
* IL-23: apatamer molecule in preclinical studies (in-licensed from Archemix)
* PD - various pre-clinical candidates
* Some 5 dozen reformulated and newly formulated nanotech products in P1, P2 and P3.
This thread is now moderated: please be civil and keep the discussion on topic (about Elan.) Shorts and Longs are both welcome with the caveat that cheerleading and slamming without reasoning and sources to back them up are not welcome. |
